Nektar Therapeutics (NKTR) to Release Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is set to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Nektar Therapeutics to post earnings of ($0.23) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. The firm had revenue of $23.49 million during the quarter, compared to the consensus estimate of $17.24 million. During the same quarter last year, the business earned ($0.27) EPS. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Price Performance

NKTR stock opened at $1.40 on Wednesday. The stock has a market capitalization of $257.71 million, a price-to-earnings ratio of -1.56 and a beta of 0.61. The company has a 50-day moving average of $1.28 and a two-hundred day moving average of $1.34. Nektar Therapeutics has a 52-week low of $0.41 and a 52-week high of $1.93.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Piper Sandler assumed coverage on Nektar Therapeutics in a report on Monday. They issued an “overweight” rating and a $7.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Nektar Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.50.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.